검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Genentech, Inc.·Ann Arbor Stage IIB Hodgkin Lympho… ORR 88%·t½ 2.7 h | |||
|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Rituxan | Methylprednisolone | Abatacept |
Overview Company | AbbVie | Roche / Genentech | Genentech, Inc. | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY | ANTIBODY | ADC | ANTIBODY |
Overview Target | TNF-α | Pompe Disease | Ann Arbor Stage IIB Hodgkin Lymphoma | Rheumatoid Arthritis |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Rheumatoid Arthritis | Rheumatoid Arthritis | Rheumatoid Arthritis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | — | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the | CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR |
MoA Biomarker | biomarkers to support personalized treatment strategies | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat | biomarker-derived score, to capture and predict the course of active lupus nephritis (LN) in adult patients |
PK/PD Half-life | — | — | 2.7 h | 14.3 h |
PK/PD Species | Rat, xenografts, which corroborat | Rabbit | Rat | Mouse, Human |
PK/PD Animal (cat.) | Rat | In vitro | Rat | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | Pharmacokinetic | pd |
Toxicology Species | Rat, xenografts, which corroborat | Rabbit | Rat | Cynomolgus monkey, Mouse, Rat, Hamster, Human |
Toxicology Animal (cat.) | Unknown | In vitro | Unknown | Mouse, Rat, NHP |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | thrombocytopenia (p<0 | — | — |
Clinical Primary efficacy | ORR 98.85% | ORR 77.3% | ORR 88% | ORR 6.35% |
Clinical ORR | 98.85% | 77.3% | 88% | 6.35% |
Clinical PFS | — | 38 | — | — |
Clinical Result source | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT00732498 | ClinicalTrials.gov NCT00057811 | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | S · 92 | B · 70 | C · 68 | C · 41 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Genentech, Inc.·Ann Arbor Stage IIB Hodgkin Lympho… ORR 88%·t½ 2.7 h | |||
|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Rituxan | Methylprednisolone | Abatacept |
Overview Company | AbbVie | Roche / Genentech | Genentech, Inc. | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY | ANTIBODY | ADC | ANTIBODY |
Overview Target | TNF-α | Pompe Disease | Ann Arbor Stage IIB Hodgkin Lymphoma | Rheumatoid Arthritis |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Rheumatoid Arthritis | Rheumatoid Arthritis | Rheumatoid Arthritis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | — | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the | CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR |
MoA Biomarker | biomarkers to support personalized treatment strategies | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat | biomarker-derived score, to capture and predict the course of active lupus nephritis (LN) in adult patients |
PK/PD Half-life | — | — | 2.7 h | 14.3 h |
PK/PD Species | Rat, xenografts, which corroborat | Rabbit | Rat | Mouse, Human |
PK/PD Animal (cat.) | Rat | In vitro | Rat | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | Pharmacokinetic | pd |
Toxicology Species | Rat, xenografts, which corroborat | Rabbit | Rat | Cynomolgus monkey, Mouse, Rat, Hamster, Human |
Toxicology Animal (cat.) | Unknown | In vitro | Unknown | Mouse, Rat, NHP |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | thrombocytopenia (p<0 | — | — |
Clinical Primary efficacy | ORR 98.85% | ORR 77.3% | ORR 88% | ORR 6.35% |
Clinical ORR | 98.85% | 77.3% | 88% | 6.35% |
Clinical PFS | — | 38 | — | — |
Clinical Result source | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT00732498 | ClinicalTrials.gov NCT00057811 | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | S · 92 | B · 70 | C · 68 | C · 41 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교